Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $43.60 Average PT from Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five analysts that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $43.60.

A number of equities analysts recently weighed in on COLL shares. Piper Sandler decreased their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a report on Tuesday, February 4th. StockNews.com cut Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 19th. Needham & Company LLC reaffirmed a "buy" rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Monday, March 24th.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL traded up $0.08 during trading hours on Wednesday, reaching $26.87. 158,635 shares of the stock traded hands, compared to its average volume of 442,988. The company has a market capitalization of $863.39 million, a P/E ratio of 11.58 and a beta of 0.76. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical has a 52-week low of $23.23 and a 52-week high of $42.29. The company's 50-day simple moving average is $28.34 and its two-hundred day simple moving average is $30.63.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts' consensus estimates of $1.54 by $0.09. The company had revenue of $181.95 million for the quarter, compared to analysts' expectations of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. Equities research analysts forecast that Collegium Pharmaceutical will post 5.62 EPS for the current year.

Insider Activity

In other news, CFO Colleen Tupper sold 10,445 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total transaction of $313,454.45. Following the transaction, the chief financial officer now directly owns 165,246 shares of the company's stock, valued at approximately $4,959,032.46. The trade was a 5.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Scott Dreyer sold 2,255 shares of the business's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $67,650.00. Following the transaction, the executive vice president now directly owns 124,421 shares in the company, valued at $3,732,630. This trade represents a 1.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 81,693 shares of company stock valued at $2,334,994. Company insiders own 2.51% of the company's stock.

Hedge Funds Weigh In On Collegium Pharmaceutical

Hedge funds have recently made changes to their positions in the business. Nisa Investment Advisors LLC raised its holdings in Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after purchasing an additional 316 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Collegium Pharmaceutical by 1.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,221 shares of the specialty pharmaceutical company's stock worth $522,000 after buying an additional 339 shares during the period. AlphaQuest LLC increased its stake in shares of Collegium Pharmaceutical by 3.0% in the 4th quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company's stock worth $366,000 after acquiring an additional 374 shares in the last quarter. Foundry Partners LLC increased its stake in shares of Collegium Pharmaceutical by 2.4% in the 4th quarter. Foundry Partners LLC now owns 16,162 shares of the specialty pharmaceutical company's stock worth $463,000 after acquiring an additional 381 shares in the last quarter. Finally, SummerHaven Investment Management LLC increased its stake in shares of Collegium Pharmaceutical by 1.9% in the 1st quarter. SummerHaven Investment Management LLC now owns 24,354 shares of the specialty pharmaceutical company's stock worth $727,000 after acquiring an additional 448 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.